AstraZeneca has had significant positive traction in the market, particularly due to wins from trials for its lung disease drug where competitors have failed. This breakthrough was a surprise which caused AstraZeneca's
shares to surge and propelled the company to the top of the FTSE 100. The COPD drug trials also had a great impact, resulting in AstraZeneca stocks jumping 4% after the surprising win. Leerink has subsequently raised AstraZeneca’s stock price target to $220. AstraZeneca has also started trading on the
New York Stock Exchange following its successful listing. This has attracted investment management firms, like Nordea, to grow holdings in AstraZeneca. In the long-term momentum category for stocks, AstraZeneca consistently comes out on top. Despite market fluctuations, AstraZeneca stocks have continued to advance.
AstraZeneca stocks recently hit an all-time high at 190.19 USD. Several reports rate it a 'Moderate Buy'. Looking forward, AstraZeneca's listing will harmonise its structure across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange.
AstraZeneca Stocks News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Sat, 28 Mar 2026 13:58:02 GMT -
Rating 9
- Innovation 5
- Information 8
- Rumor -3
